Tofacitinib Effective in Ulcerative Colitis

Save

Tofacitinib is currently approved for use in rheumatoid arthritis, but is being studied in numerous other inflammatory conditons including spondylitis, psoriasis, and psoriatic arthritis, and has also been studied in patients with ulcerative colitis (UC).

Enthesitis-Related Arthritis in Children

Save

Enthesitis-related arthritis (ERA) is an emerging subset of juvenile idiopathic arthritis (JIA) recognized for its distinctive clinical characteristics.

Venous Thromboembolism Risk Factors in ANCA-Associated Vasculitis

Save

A retrospective analysis of four European vasculitis trials analyzes the risk venous thromboembolism (VTE) with ANCA-associated vasculitis and shows that CRP, cutaneous and GI involvement and baseline creatinine were most associated with VTE risk.

Will Restricting Pharmaceutical Sales Rep Access Result in Healthcare Savings?

Save

A current JAMA report shows that the implementation of policies at academic medical centers that restricted pharmaceutical sales representative (PSR) detailing was associated with modest but significant reductions in prescribing of detailed drugs across six of eight major drug classes; however, c

NEJM: Adalimumab and MTX Effective in JIA Uveitis

Save

The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab and methotrexate is effective in reducing ocular flares in juvenile idiopathic arthritis with uveitis. 

Smoking and Worse Outcomes in Spondylitis

Save

BIRMINGHAM, England -- Smoking was a strong predictor of more severe disease in patients with axial spondyloarthritis (AxSpA), with people who had ever smoked having worse disease activity and worse quality of life than those who had never smoked, researchers reported here.

FDA Approves Abaloparatide for High Risk Patients

Save

The FDA has approved injectable Tymlos (abaloparatide) for use in postmenopausal osteoporosis patients at high risk for fracture, as the drug has been shown to reduce the risk of vertebral and nonvertebral fractures in such patients.

The RheumNow Week in Review – 28 April 2017

Save

Dr. Jack Cush reviews the news from the last week on RheumNow.com - from the ACR SOTA 2017 meeting in Chicago:

Lipstick Rheumatology

Save

A 25 year-old female recently diagnosed with seronegative rheumatoid arthritis was started on a TNF inhibitor. She came in for a follow-up visit and noted that her toenails were brittle and discolored when she removed her nail polish recently.  She is concerned that she may have psoriasis or that this may be a side effect of the TNF inhibitor.

What is your next step?

Elimination of Senescent Chondrocytes Reduces Post-Traumatic Osteoarthritis

Save

A study in the April 24 issue of Nature Medicine suggests that senescent cells in the joint contribute to age-related degenerative disease and that their removal can abrogate disease. 

Best to Rehab at Home Following Joint Replacement

Save

A New York Times article sheds light on recent evidence suggesting that those undergoing hip or knee replacement will do just as well with home therapy compared to inpatient rehabilitation following surgery.

Pregnancy Flares in RA and Spondylitis

Save

Despite the folklore, not all women with arthritis who become pregnant will improve or go into remission.  Recent studies have suggested that up to one-third of RA patients will flare during pregnancy.

EULAR/EFORT Taskforce on the Management of Fragility Fractures

Save

The morbidity associated with osteoporosis-related fragility fractures imposes tremendous socioeconomic and medical impact on patients and society.

Consensus on OP Drug Holidays

Save

Extending bisphosphonate treatment beyond 3–5 years does not confer additional benefit in low-risk populations. Treatment re-initiation (usually 1–3 years after bisphosphonate withdrawal) depends on risk factors, new fractures and bone mineral density. The evidence regarding denosumab discontinuation is limited but caution is advised, as there may be a “rebound effect” with regard to fractures.

FDA Approves Renflexis as Second Infliximab Biosimilar

Save

On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD.  In early developmental trials this agent was also called SB2.

The RheumNow Week in Review – 21 April 2017

Save

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Paradoxical Toxicities with TNF Inhibitors

Save

Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.

Inconsistent ESR & CRP in Spondylitis Patients

Save

Patients with active axial spondyloarthritis (axSpA) can lack evidence of inflammation on magnetic resonance imaging (MRI) but may develop evidence of inflammation over time.

Anti-IL-23 Therapy Effective in Crohn's Disease

Save

Lancet has reported the results of risankizumab, an interleukin-23 (IL-23) inhibitor, in Crohn's disease. Risankizumab is a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, and is being developed for Crohn's disease.

The Cost of Not Taking Medicine

Save

The NY Times points out "there is is an out-of-control epidemic in the United States that costs more and affects more people than any disease Americans currently worry about. It’s called nonadherence to prescribed medications, and it is — potentially, at least — 100 percent preventable by the very individuals it afflicts.